MedTrace Logo

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

NCT06388122 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-06-01

No results posted yet for this study

Summary

This study is being done to determine if there is a pattern associated with response to endocrine therapy alone and in combination with CDK4/6 inhibitor used for hormone receptor positive HER2 negative breast cancer.

Conditions

  • HER2-negative Breast Cancer
  • Hormone-receptor-positive Breast Cancer
  • Metastatic Breast Cancer
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2 Negative Breast Carcinoma
  • Hormone Receptor Positive Breast Carcinoma
  • Metastatic Breast Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Sponsors & Collaborators

Principal Investigators

  • Pooja Advani, MBBS, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2031-06-15
Completion
2031-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06388122 on ClinicalTrials.gov